Skip to content

Shattuck Labs, Inc. STTK Other accrued liabilities

Other accrued liabilities at other companies

Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
Immunovant, Inc. logo
Immunovant, Inc.IMVT

Other financials

Income statement

See full
Revenue-
Operating income-$15.5M-8.0%
Net income-$14.8M-7.8%
EPS (diluted)-$0.13+51.9%

Balance sheet

See full
Cash & equivalents$90.4M+48.5%
Total debt$2.9M-9.5%
Total equity$95.8M+41.8%
Total assets$102.1M+32.3%

Cash flow

See full
Operating cash flow-$13.4M-11.6%
CapEx$63.0K
Free cash flow-$13.5M-12.1%

Valuation

See full
Market cap$564.45M+1,131%
Enterprise value$476.92M-4,119%
P/S564.5×+554×

Profitability

See full
Operating margin-5,266.4%-9,520pp
Net margin-4,987.4%-8,966pp
FCF margin-4,140.8%-7,144pp

Returns & leverage

See full
Return on equity-61%-8.0pp
Debt / equity0.0×
Current ratio22.1×+13.0×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.

The official record: Shattuck Labs, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Shattuck Labs, Inc.'s other accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Shattuck Labs, Inc.'s other accrued liabilities?
Shattuck Labs, Inc. (STTK) reported other accrued liabilities of $335K in Q1 2026.
What is the long-term trend for Shattuck Labs, Inc.'s other accrued liabilities?
Over 5 years (2020 to 2025), Shattuck Labs, Inc.'s other accrued liabilities has grown at a -10.8% compound annual growth rate (CAGR), from $419K to $236K.